Jonathan Friedberg
@drjfriedberg
Lymphoma expert. Director of @WilmotCancer Rochester NY. Editor-in-Chief, Journal of Clinical Oncology @asco_pubs. Tweets and opinions are my own.
ID: 2886201454
http://www.urmc.rochester.edu/people/20880804-jonathan-w-friedberg 20-11-2014 21:50:17
2,2K Tweet
5,5K Followers
410 Following
End Point Surrogacy in First-Line CLL: Given the clear PFS benefit in patients who achieve undetectable MRD after therapy, novel strategies incorporating MRD as an endpoint are ready for evaluation as a precision approach to CLL therapy. Journal of Clinical Oncology ascopubs.org/doi/full/10.12…